GOP senators demand explanation for Administration's actions on early treatments for COVID-19
The group charged that the Administration has a "strong bias" against ivermectin and "other potential early treatment drugs."
The Facts Inside Our Reporter’s Notebook
Senator Ron Johnson of Wisconsin and 21 other Republicans are pressuring the Biden Administration to offer more early treatment options for COVID-19 to the American Public.
“Throughout the COVID-19 pandemic, public health officials have not only ignored potential early treatments, but at times seem to have participated in an aggressive campaign against the use of specific early treatment options,” the group's letter to officials stated.
The letter was addressed to Xavier Becerra, Secretary of Health and Human Services; Dr. Anthony Fauci, Director of National Institute of Allergy and Infectious Diseases; Dr. Rochelle Walensky, Director of Centers for Disease Control and Prevention; and Dr. Janet Woodcock, Acting Commissioner of Food and Drug Administration.
“Even though a basic tenet of medicine is: early detection allows for early treatment which produces better results; your agencies have overtly discouraged the use of cheap and widely-available early treatments like ivermectin in favor of expensive new drugs like Remdesivir (which costs more than $3,000 per treatment)," the letter said.
The group charged that the Administration a "strong bias" against ivermectin and "other potential early treatment drugs."
The letter from the Republican senators comes as the Biden administration started capping how many doses of anti-body treatments it would be giving to states.
"We strongly believe you should explain to the American people why your agencies have failed to sufficiently examine and ensure access to a growing list of drugs being used by doctors who have had the courage to ignore NIH’s ongoing compassionless guideline of doing virtually nothing until COVID-19 patients are so sick they require hospitalization," the group wrote.
Sen. Johnson previously held two hearings on early treatment of COVID-19.